Lupin Ltd (LUPIN) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Lupin Ltd enters its Q1 FY 2026-2027 results facing the challenge of balancing strong domestic growth against competitive headwinds in its critical US generics business. Investors will be closely watching the EBITDA margin trajectory and the revenue run-rate for key US products following the loss of exclusivity on major assets.

Lupin Ltd Q1 Results Date and Time

The board meeting is scheduled for August 06, 2026, to consider the audited financial results.

What to expect from Lupin Ltd's Q1 FY27 results

Lupin's Q1 FY27 performance is expected to be buoyed by a strong domestic India prescription business, which historically tracks ahead of the broader market's ~13.5% YoY growth. While the company benefits from a ~9–10% rupee depreciation tailwind on its US revenue, management has guided for high single-digit to low double-digit USD erosion in the US segment for FY27 due to increased competition for products like Tolvaptan. The EBITDA margin is expected to trend toward the guided 24–25% range for the fiscal year, representing a moderation from the Q4 FY26 level of 29.4%. Analysts will focus on the quarterly run-rate of key US generics and the impact of the ~8% of sales R&D spend on overall profitability. The upcoming call will likely clarify the clean profit trajectory now that the exceptional items from the previous fiscal year, such as the Rs. 847.55 Cr Mirabegron settlement, have been accounted for.

Key Things To Watch

Performance vs Guidance Tracking: Monitoring progress against management's stated FY27 targets.

• Group Revenue Growth: High single-digit to double-digit target for FY27
• EBITDA Margin: ~25% target for FY27
• US Business Revenue: Maintain >USD 1 billion run-rate for FY27
• R&D Spend: ~8% of sales target for FY27

Competitive and Product Updates: Tracking the revenue contribution of key generics and new launches.

• Tolvaptan: Quarterly run-rate stabilization vs the guided USD 275–300 Mn range
• Pegfilgrastim: Revenue contribution in Q1 post-launch
• Ranibizumab (Ranluspec): Launch progress following June 04, 2026, FDA approval

Regulatory and Compliance Status: Updates on facility remediation efforts impacting product approvals.

• Pithampur Unit II: Remediation progress for OAI classification
• Ankleshwar facility: Impact of clean EIR received May 28, 2026, on future approvals

Strategic Acquisitions: Integration status of recent portfolio expansions.

• VISUfarma acquisition: Integration update and initial revenue contribution
• Renascience Pharma: Update on post-acquisition operations